Wild-type P53 Delivery
Wild-type P53 Delivery - Related Videos
14:57
Yeast As a Chassis for Developing Functional Assays to Study Human P53
0 Views •
Cited by 16 •
2019
Presented here are four protocols to construct and exploit yeast Saccharomyces cerevisiae reporter strains to study human P53 transactivation potential, impacts of its various cancer-associated mutations, co-expressed interacting proteins, and the effects of specific small molecules.
03:28
Quantifying the Replication Efficiency of Wild-Type and Mutant Viruses
0 Views •
2026
Source: Manocheewa, S., et al. Pairwise Growth Competition Assay for Determining the Replication Fitness of Human Immunodeficiency Viruses. J. Vis. Exp. (2015)This video demonstrates the use of reverse transcription quantitative PCR (RT-qPCR) to quantify the replication efficiency of wild-type and mutant viruses following infection of human blood immune cells.
05:11
Wild-Type Blocking PCR to Detect Low-Frequency Somatic Mutations
0 Views •
2025
This video describes wild-type blocking polymerase chain reaction, or WTB-PCR, which detects somatic mutations. The PCR-based technique uses a locked nucleic acid, or LNA, an oligonucleotide that binds to its complementary wild-type allele and blocks its elongation. The blocking selectively allows the amplification of low-level mutant alleles over their wild-type variants in the sample.
03:03
Phenotypic Comparison of Wild-Type and Mutant Strains of Streptomyces coelicolor
0 Views •
2025
Source: Bennett, J. A., et al. Visual and Microscopic Evaluation of Streptomyces Developmental Mutants. J. Vis. Exp. (2018)This video demonstrates the cultivation and phenotypic comparison of wild-type and mutant Streptomyces coelicolor strains. It outlines procedures for minimizing spontaneous mutations, preventing cross-contamination, and promoting bacterial growth through proper plating techniques. Finally, the video highlights visual differences in colony morphology to illustrate the...
02:04
Transfection of Wild-Type Amoeba via Electroporation with Bacterial Feeding Support
0 Views •
2025
Source: Paschke, P., et al. Genetic Engineering of Dictyostelium discoideum Cells Based on Selection and Growth on Bacteria. J. Vis. Exp. (2019).This video demonstrates the procedure for introducing a plasmid carrying a target gene into amoeba cells via electroporation, followed by recovery in a bacterial supplement to enable efficient gene delivery in wild-type amoeba.
FAQs
Experiments may introduce either a functional TP53 gene or p53 protein, so the cargo determines what is being transported into target cells. The central readout is whether p53 signaling becomes functionally restored, rather than merely whether cargo reaches a cell. This distinction helps connect carrier performance with changes in tumor-cell behavior.
The observed result may be cell-cycle arrest, activation of DNA-damage responses, or apoptosis. These outcomes reflect different consequences of re-establishing tumor-suppressor activity in cells whose p53 function was absent, mutated, or inactive. Tracking which response predominates helps researchers evaluate how replacement influences tumor-cell behavior.
Viral vectors, nanoparticles, and engineered carriers provide different design frameworks for transporting p53 cargo. Delivery efficiency depends on how effectively a system reaches target cells, while targeting and controlled release are important because they may improve selectivity and limit effects on healthy tissues. These variables make carrier design central to evaluating therapeutic potential.
A bioengineering workflow begins by selecting a functional TP53 gene or p53 protein, pairing it with a delivery system, and transporting the cargo into target cells. Researchers then examine whether p53 signaling is restored and whether cells show arrest, DNA-damage responses, or apoptosis. Comparing these outcomes with delivery performance links design choices to biological effects.
Researchers can use Wild-type P53 Delivery to test how replacing defective p53 influences tumor-cell behavior, including responses such as cell-cycle arrest or apoptosis. The strategy also supports gene-therapy research, cancer-biology studies, and precision drug-delivery investigations. These applications connect molecular replacement with engineered transport and measurable cellular outcomes.
Within bioengineering, the approach connects cargo selection, carrier construction, cellular targeting, and biological readouts. Continued advances focus on improving delivery efficiency while limiting effects on healthy tissues, with targeting and controlled release identified as important design directions. This makes the system a research platform for testing how engineered transport changes p53-dependent tumor-cell responses.